Historical Valuation
Chemomab Therapeutics Ltd (CMMB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -34.53. The fair price of Chemomab Therapeutics Ltd (CMMB) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.81
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Chemomab Therapeutics Ltd (CMMB) has a current Price-to-Book (P/B) ratio of 0.98. Compared to its 3-year average P/B ratio of 1.30 , the current P/B ratio is approximately -24.57% higher. Relative to its 5-year average P/B ratio of 1.43, the current P/B ratio is about -31.32% higher. Chemomab Therapeutics Ltd (CMMB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -109.62%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -78.45% , the current FCF yield is about -100.00% lower.
P/B
Median3y
1.30
Median5y
1.43
FCF Yield
Median3y
-109.62
Median5y
-78.45
Competitors Valuation Multiple
AI Analysis for CMMB
The average P/S ratio for CMMB competitors is 5.72, providing a benchmark for relative valuation. Chemomab Therapeutics Ltd Corp (CMMB.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CMMB
1Y
3Y
5Y
Market capitalization of CMMB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CMMB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CMMB currently overvalued or undervalued?
Chemomab Therapeutics Ltd (CMMB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -34.53. The fair price of Chemomab Therapeutics Ltd (CMMB) is between to according to relative valuation methord.
What is Chemomab Therapeutics Ltd (CMMB) fair value?
CMMB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Chemomab Therapeutics Ltd (CMMB) is between to according to relative valuation methord.
How does CMMB's valuation metrics compare to the industry average?
The average P/S ratio for CMMB's competitors is 5.72, providing a benchmark for relative valuation. Chemomab Therapeutics Ltd Corp (CMMB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Chemomab Therapeutics Ltd (CMMB) as of Jan 09 2026?
As of Jan 09 2026, Chemomab Therapeutics Ltd (CMMB) has a P/B ratio of 0.98. This indicates that the market values CMMB at 0.98 times its book value.
What is the current FCF Yield for Chemomab Therapeutics Ltd (CMMB) as of Jan 09 2026?
As of Jan 09 2026, Chemomab Therapeutics Ltd (CMMB) has a FCF Yield of 0.00%. This means that for every dollar of Chemomab Therapeutics Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for Chemomab Therapeutics Ltd (CMMB) as of Jan 09 2026?
As of Jan 09 2026, Chemomab Therapeutics Ltd (CMMB) has a Forward P/E ratio of -11.19. This means the market is willing to pay $-11.19 for every dollar of Chemomab Therapeutics Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Chemomab Therapeutics Ltd (CMMB) as of Jan 09 2026?
As of Jan 09 2026, Chemomab Therapeutics Ltd (CMMB) has a Forward P/S ratio of 0.00. This means the market is valuing CMMB at $0.00 for every dollar of expected revenue over the next 12 months.